- Home
- SOR vs XOMA Comparison
SOR vs XOMA Comparison
Compare SOR & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- XOMA
- Stock Information
- Founded
- SOR 1968
- XOMA 1981
- Country
- SOR United States
- XOMA United States
- Employees
- SOR N/A
- XOMA N/A
- Industry
- SOR Investment Managers
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- XOMA Health Care
- Exchange
- SOR Nasdaq
- XOMA Nasdaq
- Market Cap
- SOR 361.3M
- XOMA 355.6M
- IPO Year
- SOR N/A
- XOMA N/A
- Fundamental
- Price
- SOR $45.26
- XOMA $26.90
- Analyst Decision
- SOR
- XOMA Strong Buy
- Analyst Count
- SOR 0
- XOMA 2
- Target Price
- SOR N/A
- XOMA $81.50
- AVG Volume (30 Days)
- SOR 16.2K
- XOMA 30.4K
- Earning Date
- SOR 01-01-0001
- XOMA 11-07-2024
- Dividend Yield
- SOR 7.24%
- XOMA N/A
- EPS Growth
- SOR N/A
- XOMA N/A
- EPS
- SOR 6.50
- XOMA N/A
- Revenue
- SOR N/A
- XOMA $21,606,000.00
- Revenue This Year
- SOR N/A
- XOMA $509.54
- Revenue Next Year
- SOR N/A
- XOMA $26.20
- P/E Ratio
- SOR $6.41
- XOMA N/A
- Revenue Growth
- SOR N/A
- XOMA 389.82
- 52 Week Low
- SOR $36.41
- XOMA $16.00
- 52 Week High
- SOR $42.75
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- SOR 54.60
- XOMA 34.87
- Support Level
- SOR $44.00
- XOMA $27.01
- Resistance Level
- SOR $45.47
- XOMA $30.86
- Average True Range (ATR)
- SOR 0.65
- XOMA 1.25
- MACD
- SOR -0.05
- XOMA -0.54
- Stochastic Oscillator
- SOR 49.57
- XOMA 1.63
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.